Targeting CD133 for imaging and therapy in prostate cancer
靶向 CD133 用于前列腺癌的成像和治疗
基本信息
- 批准号:10470959
- 负责人:
- 金额:$ 35.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:Androgen ReceptorAntiandrogen TherapyAntibodiesBeta ParticleBiodistributionBiopsyBloodCancer ModelCancer PatientCell Cycle StageCell LineCellsClinicalDataDevelopmentDiseaseDoseDrug KineticsEngineeringEpitopesGenerationsGoalsHumanImageImmunoglobulinsImmunohistochemistryInnovative TherapyIntegral Membrane ProteinKnowledgeLabelLeadLengthLibrariesMalignant NeoplasmsMalignant neoplasm of prostateMetastatic Neoplasm to the BoneMetastatic Prostate CancerModalityModelingMonitorNeoplasm MetastasisOryctolagus cuniculusPatientsPeptidesPhage DisplayPositron-Emission TomographyPropertyRadiation therapyRadioimmunotherapyRadiolabeledReceptor SignalingResearchResistanceSafetyStainsStudy modelsSurfaceSurface AntigensTestingTherapeuticTissue MicroarrayTreatment EfficacyValidationVariantVertebral columnVisceraVisceral metastasisXenograft ModelXenograft procedureandrogen deprivation therapyantibody engineeringbasebonebone imagingburden of illnesscancer stem cellchemotherapyclinical translationclinically relevantcombatdensitydisorder subtypedosimetryeffective therapyglycosylationimaging agentimaging modalityimaging probeimaging studyin vitro Modelin vivoinnovationlongitudinal positron emission tomographymenmouse modelnovelnovel therapeuticsoverexpressionpatient derived xenograft modelpatient responsepharmacodynamic biomarkerpublic health relevancesingle photon emission computed tomographystandard of carestem cell biomarkerssubcutaneoustargeted agenttherapeutic evaluationtherapeutically effectivetherapy developmenttooltreatment responsetumoruptake
项目摘要
ABSTRACT
Aggressive variant prostate cancer (AVPC) arises in men who have failed treatment with second-generation
anti-androgen therapy. Not driven by the androgen receptor-signaling axis, effective treatment options do not
exist for AVPC and new, innovative therapies are urgently needed. Critical to the development of novel
therapeutics is the ability to accurately image disease burden in AVPC patients. An imaging modality that can
detect both the bone and visceral metastases associated with AVPC does not exist. The overall goal of this
project is to develop positron emission tomography (PET) imaging probes and radioimmunotherapy (RIT) agents
by targeting a newly identified cell-surface antigen unique to AVPC with novel antibody constructs. Using human
antibody phage display, we recently identified a single chain variable fragment (scFv) that specifically bound to
a glycosylation-independent epitope on the peptide backbone of the transmembrane protein CD133. Often
characterized as a cancer stem cell marker, the function of CD133 in cancer is unknown. All commercially
available antibodies for CD133 recognize glycosylation-dependent epitopes that vary between cells and at
different stages of the cell cycle. Immunohistochemistry (IHC) with these antibodies yield inconsistent results
and poor staining quality; thus contributing to our limited knowledge of CD133. Our scFv for CD133, termed A10,
was converted into a full-length immunoglobulin (IA10) for IHC analysis on patient biopsies and tissue
microarrays. Remarkably, we found that CD133 was only expressed in bone and visceral metastases of men
who had developed AVPC. As a single-photon emission computed tomography imaging agent, IA10 was able to
image CD133 expression in vivo. In biodistribution studies, IA10 and a smaller minibody construct version
(MA10) both demonstrated high tumor uptake and favorable pharmacokinetics. The high tumor uptake of the
A10 antibody constructs was the direct result of their rapid internalization by CD133-expressing cells making
them ideal candidates for longitudinal PET imaging and RIT. In this proposal, we will evaluate the utility of IA10
and MA10 as PET probes in cell line-derived and patient-derived xenograft models of AVPC and evaluate CD133
as a pharmacodynamic biomarker (Aim 1) then determine the therapeutic potential of IA10 radiolabeled with
177Lu for beta particle RIT in subcutaneous and metastatic xenografts using single and fractionated doses (Aim
2). Our preliminary data strongly suggest that we have developed potent tools for AVPC that possess the
potential to result in a dramatic shift in how the disease is treated.
摘要
侵袭性变异型前列腺癌(AVPC)发生在第二代前列腺癌治疗失败的男性中
抗雄激素治疗不受雄激素受体信号传导轴的驱动,有效的治疗选择不
AVPC存在,迫切需要新的创新疗法。小说发展的关键
治疗是准确成像AVPC患者疾病负担的能力。一种成像模态,
检测骨和内脏转移与AVPC不存在。这个项目的总体目标是
项目是开发正电子发射断层扫描(PET)成像探针和放射免疫治疗(RIT)试剂
通过用新的抗体构建体靶向新鉴定的AVPC特有的细胞表面抗原。使用人
抗体噬菌体展示,我们最近确定了一个单链可变片段(scFv),特异性结合
跨膜蛋白CD 133的肽骨架上的糖基化非依赖性表位。经常
尽管CD 133被表征为癌症干细胞标志物,但其在癌症中的功能尚不清楚。所有市
可用的CD 133抗体识别糖基化依赖性表位,这些表位在细胞之间变化,
细胞周期的不同阶段。这些抗体的免疫组织化学(IHC)产生不一致的结果
和染色质量差;从而导致我们对CD 133的了解有限。我们的针对CD 133的scFv,称为A10,
转化为全长免疫球蛋白(IA 10),用于对患者活检和组织进行IHC分析
微阵列值得注意的是,我们发现CD 133仅在男性的骨和内脏转移中表达,
开发了AVPC。作为单光子发射计算机断层扫描成像剂,IA 10能够
体内成像CD 133表达。在生物分布研究中,IA 10和较小的微抗体构建体版本
(MA 10)两者均显示高肿瘤摄取和有利的药代动力学。肿瘤的高吸收
A10抗体构建体是其通过表达CD 133的细胞快速内化的直接结果,
它们是纵向PET成像和RIT的理想候选者。在本提案中,我们将评估IA 10的效用
和MA 10作为PET探针在AVPC的细胞系来源的和患者来源的异种移植物模型中,
作为药效学生物标志物(目的1),然后确定用放射性标记的IA 10的治疗潜力
177 Lu用于皮下和转移性异种移植物中的β颗粒RIT,使用单次和分次剂量(Aim
2)。我们的初步数据有力地表明,我们已经为AVPC开发了具有以下功能的有效工具:
可能导致疾病治疗方式的巨大转变。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Aaron Matthew LeBeau其他文献
Aaron Matthew LeBeau的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Aaron Matthew LeBeau', 18)}}的其他基金
Viral vector technology for cell type specific gene delivery
用于细胞类型特异性基因传递的病毒载体技术
- 批准号:
10796647 - 财政年份:2022
- 资助金额:
$ 35.57万 - 项目类别:
Viral vector technology for cell type specific gene delivery
用于细胞类型特异性基因传递的病毒载体技术
- 批准号:
10365787 - 财政年份:2022
- 资助金额:
$ 35.57万 - 项目类别:
Viral vector technology for cell type specific gene delivery
用于细胞类型特异性基因传递的病毒载体技术
- 批准号:
10581499 - 财政年份:2022
- 资助金额:
$ 35.57万 - 项目类别:
Targeting CD133 for imaging and therapy in prostate cancer
靶向 CD133 用于前列腺癌的成像和治疗
- 批准号:
10410106 - 财政年份:2021
- 资助金额:
$ 35.57万 - 项目类别:
Targeting CD133 for imaging and therapy in prostate cancer
靶向 CD133 用于前列腺癌的成像和治疗
- 批准号:
10653106 - 财政年份:2021
- 资助金额:
$ 35.57万 - 项目类别:
Cyclic Peptide Protease Inhibitors for the Treatment of Prostate Cancer
用于治疗前列腺癌的环肽蛋白酶抑制剂
- 批准号:
10545171 - 财政年份:2020
- 资助金额:
$ 35.57万 - 项目类别:
Cyclic Peptide Protease Inhibitors for the Treatment of Prostate Cancer
用于治疗前列腺癌的环肽蛋白酶抑制剂
- 批准号:
10321260 - 财政年份:2020
- 资助金额:
$ 35.57万 - 项目类别:
Cyclic Peptide Protease Inhibitors for the Treatment of Prostate Cancer
用于治疗前列腺癌的环肽蛋白酶抑制剂
- 批准号:
10062931 - 财政年份:2020
- 资助金额:
$ 35.57万 - 项目类别:
Cyclic Peptide Protease Inhibitors for the Treatment of Prostate Cancer
用于治疗前列腺癌的环肽蛋白酶抑制剂
- 批准号:
10408279 - 财政年份:2020
- 资助金额:
$ 35.57万 - 项目类别:
Novel Radioimmunotherapy Strategies for Prostate Cancer
前列腺癌的新型放射免疫治疗策略
- 批准号:
10470949 - 财政年份:2019
- 资助金额:
$ 35.57万 - 项目类别:
相似海外基金
Refining Antiandrogen Therapy for Positron Emission Tomography
改进正电子发射断层扫描的抗雄激素疗法
- 批准号:
8555296 - 财政年份:2000
- 资助金额:
$ 35.57万 - 项目类别:
Refining Antiandrogen Therapy for Positron Emission Tomography
改进正电子发射断层扫描的抗雄激素疗法
- 批准号:
8567120 - 财政年份:
- 资助金额:
$ 35.57万 - 项目类别:
The role of the platelet-leucocyte axis in antiandrogen therapy induced cardiovascular disease
血小板-白细胞轴在抗雄激素治疗诱发的心血管疾病中的作用
- 批准号:
537070747 - 财政年份:
- 资助金额:
$ 35.57万 - 项目类别:
WBP Fellowship
Refining Antiandrogen Therapy for Positron Emission Tomography
改进正电子发射断层扫描的抗雄激素疗法
- 批准号:
8725587 - 财政年份:
- 资助金额:
$ 35.57万 - 项目类别:
Refining Antiandrogen Therapy for Positron Emission Tomography
改进正电子发射断层扫描的抗雄激素疗法
- 批准号:
8909067 - 财政年份:
- 资助金额:
$ 35.57万 - 项目类别: